Literature DB >> 2909723

Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.

W K Anderson1, D Bhattacharjee, D M Houston.   

Abstract

A series of bis(carbamate) derivatives of 1,2-substituted 4,5-bis(hydroxymethyl)imidazoles were prepared and evaluated against murine P388 lymphocytic leukemia. Electron-withdrawing substituents at either N-1 or C-2 gave rise to inactive compounds. However, electron-donating substituents gave active compounds and the 2-(methylthio)-1-methyl derivative 2i (carmethizole), as the bis(N-methylcarbamate), was found to be very active. The derivative 2i, referred to by the name carmethizole, was also shown to be active against the MX-1 mammary xenograft, the human amelanotic melanoma cell line (LOX) xenograft, the M5076 sarcoma, and L1210 lymphocytic leukemia. The solution stability, water solubility, pKa, and log P of carmethizole are also reported.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909723     DOI: 10.1021/jm00121a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.

Authors:  Jianjun Chen; Zhao Wang; Yan Lu; James T Dalton; Duane D Miller; Wei Li
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

2.  4-Carb-oxy-2-methyl-1H-imidazol-3-ium-5-carboxyl-ate monohydrate.

Authors:  Yu-Ping Guo
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-12-06

3.  Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Authors:  W R Waud; J Plowman; S D Harrison; D J Dykes; W K Anderson; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog.

Authors:  J I Brodfuehrer; T J Wilke; D H Kinder; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.